Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND Little is known about the long-term outcomes of repeated ketamine infusions for depression. We conducted a retrospective chart review to investigate outcomes of maintenance intravenous ketamine treatment at Massachusetts General Hospital. METHODS Eighty-five patients with treatment-resistant depression (TRD) who started intravenous ketamine from October 2018 to November 2019 were examined. Symptom severity was evaluated with the 16-item Quick Inventory of Depressive Symptomatology-Self Report scale (QIDS-SR16) at every visit prior to administration. The initial ketamine dose was usually 0.5 mg/kg infused over 40 min. Intravenous ketamine was administered twice-weekly for three weeks in an induction phase, followed by maintenance with a variable administration schedule and dose. Response was defined as a ≥50% reduction in total QIDS-SR16 score from baseline. RESULTS Forty (47.1%) of the 85 patients who started treatment discontinued during or right after the induction phase; 3 (3.5%) were still on induction at the time of this report, and 42 (49.4%) transitioned to maintenance after completing induction. Among these patients, 14 (16.5%) discontinued during maintenance and 28 (32.9%) continued on maintenance. The mean ketamine dosage during maintenance was 0.91±0.28 mg/kg. Fifteen out of 82 patients (18.3%) responded to induction treatment and 6 (7.3%) remained in responder status at the time of data analysis during maintenance. Three patients discontinued ketamine due to side-effects. CONCLUSIONS Despite the apparently low response rate in QIDS-SR16 scores and considerable out-of-pocket costs, almost half of real-world outpatients with TRD decided to continue with maintenance ketamine treatment due to perceived significant improvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“Symptom severity is evaluated with the 16-item Quick Inventory of Depressive Symptomatology-Self Report scale (QIDS-SR 16 ) (Rush et al., 2003) and Clinical Global Impression-Severity/Improvement scales (CGI-S/I) before administration and at every subsequent visit.”
MethodmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“We are aware that in pre-clinical studies, there is data considering that ketamine may have a U-shaped antidepressant effect and that higher doses may be less effective for depression-like behaviors in rodents (Chowdhury et al., 2017; Li et al., 2010).”
BackgroundDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795 · cited 3×
“In 2019, Janssen published controlled data regarding long-term efficacy and safety of administration of intranasal esketamine in 297 patients with TRD, followed for up to 92 weeks (Daly et al., 2019).”
BackgroundMethodSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Morgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 1×
“Multiple clinical trials have demonstrated that even a single subanesthetic dose of intravenous ketamine has a rapid-acting antidepressant e ff ect (Cusin et al., 2017; Diamond et al., 2014; Fava et al., 2018; Singh et al., 2016).”
BackgroundFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433 · cited 2×
“Multiple clinical trials have demonstrated that even a single subanesthetic dose of intravenous ketamine has a rapid-acting antidepressant e ff ect (Cusin et al., 2017; Diamond et al., 2014; Fava et al., 2018; Singh et al., 2016).”
BackgroundSelf-citationGrunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431 · cited 1×
“The response rate to intravenous ketamine in our clinic appears signi fi cantly lower compared to rates published in randomized controlled trials (RCTs), which range from 30% to 70% on day 1 (Aan Het Rot et al., 2012; Fava et al., 2018; Grunebaum et al., 2018).”
BackgroundKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
Aaronson, S. T., Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., Reimherr, F. W., Schwartz, T. L., & Zajecka, J. M. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16010034 · Cited by 381 · cited 1×
“In an observational study to examine the e ff ectiveness of adjunctive Vagal Nerve Stimulation (VNS), the cumulative response rate of treatment-as-usual at 3 months was less than 10% for those who had 7.3 failed treatments for depression (Aaronson et al., 2017).”
BackgroundInfluentialChowdhury, G. M. I., Zhang, J., Thomas, M., Banasr, M., Ma, X., Pittman, B., Bristow, L., Schaeffer, E., Duman, R. S., Rothman, D. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.34 · Cited by 197 · cited 1×
“We are aware that in pre-clinical studies, there is data considering that ketamine may have a U-shaped antidepressant effect and that higher doses may be less effective for depression-like behaviors in rodents (Chowdhury et al., 2017; Li et al., 2010).”
BackgroundGrunebaum, M. F., Ellis, S. P., Keilp, J. G., Moitra, V. K., Cooper, T. B., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12487 · Cited by 174 · cited 2×
“Similarly, the decrease in suicidal ideation severity after initial series of infusions was observed in a relatively low percentage of patients, compared with the reported effectiveness of ketamine treatment for decreasing suicidal ideation in the literature (Grunebaum et al., 2017).”
ResultFrye, M. A., Blier, P., & Tye, S. J. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000316 · Cited by 75
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., Saah, T. C., Dunlop, B. W., & McDonald, W. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.025 · Cited by 70
Zimmerman, M., Chelminski, I., & Posternak, M. A. (2004) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000110279.23893.82 · Cited by 58 · cited 1×
“Participants in clinical trials do not usually reflect patients seen in clinical practice because of strict selection criteria (Zimmerman et al., 2004).”
Background
Cited by
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Smith-Apeldoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00317-0 · Cited by 169
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P., & Robison, R. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04268-5 · Cited by 24
Metadata
- Authors
- Sakurai, H., Jain, F., Foster, S., Pedrelli, P., Mischoulon, D., Fava, M., & Cusin, C.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 276
- Pages
- 660-666
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W3044972280
- Cited by
- 45
- References
- 15
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.